January 27, 2012: Quotient Bioresearch, a UK-based provider of outsourced development services, has undergone a management buyout financed by TA Associates, a current private equity shareholder. Quotient employs more than 500 people and serves the pharmaceutical and life science sector on a global basis, principally targeting the early stages of drug development based upon chemistry, metabolism, bioanalytical and clinical capabilities. The company had a like-for-like revenue increase of more than 20 per cent on last year. The management buyout was led by the company’s CEO, Roger Burdett, and its CFO, Gordon Cameron.
- RSS Feed
